Q32 Bio (QTTB) Preferred Stock Liabilities (2017 - 2023)
Q32 Bio (QTTB) recorded quarterly Preferred Stock Liabilities of $111.4 million in Q4 2023, down 19.1% quarter-over-quarter from $137.8 million in Q1 2018.
Q32 Bio (QTTB) Preferred Stock Liabilities (2017 - 2023) Analysis & Trends
Q32 Bio's Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $111.4 million for Q4 2023.
- In Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $111.4 million; the TTM figure through Dec 2023 stood at $111.4 million (changed N/A YoY), while the FY2023 annual figure was $111.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $111.4 million for Q4 2023 at Q32 Bio, down from $137.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $111.4 million in Q4 2023 to a low of $111.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Q32 Bio | 177.18 Mn | 126.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 111.45 Mn |
| Mar 31, 2018 | 137.76 Mn |
| Dec 31, 2017 | 137.76 Mn |